Oncolytics Target REDUCED and 4 Stock Analyses Buzzing Today
Oncolytics Biotech Inc. (NASDAQ:ONCY) target has been lowered by RBC Capital following the company’s report of inconclusive data in regards to its treatment for head and neck cancer. The firm does not believe that the next Phase III trial of the treatment wil begin until the middle of 2013, but it has decided to keep its Outperform rating on the stock with the intentions of following up with management.
Dick’s Sporting Goods Inc. (NYSE:DKS): According to JPMorgan, Amazon (NASDAQ:AMZN)will begin a website for the sporting goods market soon, this will have the address www.afterschool.com, but this website will not possess the core athlete assortment offered by Dick’s Sporting Goods. The firm believes that Amazon is probably targeting a subset of Dick’s customer base, and it has decide to keep its Overweight rating on the stock.
Biogen Idec Inc. (NASDAQ:BIIB): Following the approval of Sanofi’s (NYSE:SNY) Aubagio on time and without a panel, RBC Capital views this development as lowering the probability of Biogen’s BG-12 having to deal with any regulatory difficulties. The firm views the outlook for Biogen’s ALS treatment as risky, but continues to recommend purchasing the stock on any pullback related to negative data for the medication. The firm keeps its Outperform rating on the stock.
SanDisk Corp. (NASDAQ:SNDK) estimates have been increased by Morgan Stanley due to an improved NAND outlook, as well as reduced capital spending levels. Shares have an Overweight rating.
Darling International Inc. (NYSE:DAR): BMO Capital predicts that the company’s sales volume for the summer and through 1H13 will exceed expectations. The firm believes that the company possesses numerous long-term opportunities, and it keeps an Outperform rating and a $21 target on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>